In an interesting editorial in the Sep tember issue, Alda and Kapczinski ex plore the clinical staging model as ap plied to bipolar disorder, 1 consider some of the strengths and weaknesses of this approach and go on to comment on the predictions suggested by Scott and colleagues. 2 Although the editorial rightly points out some of the limita tions of current staging models, many of the authors' conclusions draw heavi ly on 2 ideas that are not core to most staging models, namely that staging is largely about established disorder and that disease progression is predom inantly described by severity, with co morbidities treated as separate entities. Since these concepts have implications ranging from etiology to neurobiology, nosology and even clinical services, we believe that these additional issues need to be highlighted even though we agree with many of the sentiments and key messages in the editorial.
First, although the editorial's overall focus is on later stages of bipolar disor der, an important consideration for most of the staging models developed across mental health is the emphasis on early stages and subthreshold con ditions -especially those presenting during the peak age of onset for severe mental disorders (15-25 yr) . Unlike older adults with established supra threshold disorders that meet tradi tional diagnostic criteria (where Alda and Kapczinski's distinction between "illness progression or typology of ill ness" may hold true), the early course of illness and even the longterm tra jectories of many earlystage, sub threshold syndromes are pluripoten tial and much less predictable (e.g., some evolve into recurrent depression, bipolar disorder, or psychosis; others represent timelimited adjustment problems with no further episodes of any disorder). 3, 4 Staging models, applied in psychiatry as in general medicine, focus primarily on where an individual is located on a con tinu um -from an asymptomatic atrisk state through to endstage diseasethereby examining the full trajectory and course of illness from its early be ginnings. Also in staging models, ill ness progression is not just about symptom severity; rather, it involves disease extension. In cancer, for exam ple, the size of a primary tumour, its spread to other locations within the body and involvement of other sys tems are critical measures of stage in the tumour-node-metastasis model.
Second, staging models take a life course perspective that transforms the impression of multiple lifetime psychi atric comorbidities (measured cross sectionally), recognizing that many of these may in fact be artifactual or tran sitory. In reality the picture is one of heterotypic continuities, with early, less specific stages of disorder poten tially evolving into more specific diag noses. This is commonly observed in general medicine, where obesity may be a precursor to diabetes, and obesity and hypertension may be comorbid with each other while also being pre cursors to heart disease. 5, 6 Similarly, bipolarspectrum features (e.g., brief hypomania) may be a persistent dis ease pattern in older adults, yet when occurring in young people they may reflect a more dynamic state, repre senting an early stage of an illness tra jectory; studies have demonstrated that about 20% of such cases progress to mania within 12-18 months. 7 Furthermore, Alda and Kapczinski state that insufficient data exist to judge whether earlier treatments have better risk:benefit ratios than later ones. However, treatment in staging models dictates that interventions should be age and stageappropriate. 8 This is especially pertinent for early subthreshold stages of illness, which may be selflimiting conditions or can revert to mild or nonspecific symp toms, especially with appropriate interventions. Because of this poten tial, we would neither anticipate nor recommend that firstline treatments for established bipolar disorder, such as lithium or anticonvulsants, be pre scribed for subsyndromal, nonspecific conditions. 9 As these represent the early stages of "potential bipolarity," the illness trajectory may still be un clear, and symptoms may overlap con siderably with the early stages of other disorders. There is no evidence that these traditional treatments would be effective or appropriate. Overall, the risk:benefit ratio of psychosocial treat ments is significantly lower than for diseasespecific psychopharmacology, certainly in cases of emerging psycho sis 10 and, as more recently suggested, in cases of stages 0-2 of bipolar disor der.
11 This is why many services offer nonpharmacological interventions to the large numbers of helpseeking youth presenting with transdiagnostic earlystage disorders.
Alda and Kapczinski rightly point out that we cannot at this point dem onstrate a change in the pattern of any mental disorder because of early inter vention. However, in general medi cine, the application of clinical staging models to the treatment of melanoma and breast cancer demonstrates un equivocally that early intervention does change the distribution and prog nosis of disease. 12 Of course, general medicine has the advantage that the pathophysiological boundaries be tween clinical stages can be measured with biomarkers rather than relying on clinical phenotypes. 13 The new staging model of under standing clinical phenotypes repre sents a paradigm shift that has major implications for current research. It highlights that in order to identify bio markers of illness onset and progres sion rather than treatment response, researchers must focus on early stages -especially atrisk syndromes (often designated as stage 0 and 1a) and subthreshold syndromes (stage 1b) as some of these will evolve to a fullthreshold disorder meeting tradi tional diagnostic criteria (stage 2). 14 Perhaps most of all staging models pose a fundamental question for Letters psychiatry, namely whether we need models for different disorders if their trajectories (especially early on) over lap in so many ways (e.g., genetics, neuropsychological profile, oxidative stress, sleep-wake cycle). 15 Pluripoten tial outcomes, transdiagnostic risk fac tors that could explain mental and physical comorbities, age at peak onset and transitions of subthreshold syn dromes often defy classification under current schema, but are likely to be a key part of the new psychiatry. 16 If we decide to adopt clinical staging mod els, whichever version we choose will challenge us all, as it is not just a case of putting old wine into new bottles (or young wine into old ones!).
